TF and cancer: The effect of these EVs on thrombosis was further underscored by a study from Thomas et al. (Thomas et al., 2009) demonstrating binding of cancer cell-derived EVs, which expressed TF and PSGL-1 (P-selectin glycoprotein ligand 1), to activated platelets at sites of vascular injury in vivo.